Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Identification of Outer Membrane and Exoproteins of Carbapenem-Resistant Multilocus Sequence Type 258 Klebsiella pneumoniae.

Brinkworth AJ, Hammer CH, Olano LR, Kobayashi SD, Chen L, Kreiswirth BN, DeLeo FR.

PLoS One. 2015 Apr 20;10(4):e0123219. doi: 10.1371/journal.pone.0123219. eCollection 2015.

2.

Interactions of the vaccinia virus A19 protein.

Satheshkumar PS, Olano LR, Hammer CH, Zhao M, Moss B.

J Virol. 2013 Oct;87(19):10710-20. doi: 10.1128/JVI.01261-13. Epub 2013 Jul 24.

3.

Serologic reactivity to the emerging pathogen Granulibacter bethesdensis.

Greenberg DE, Shoffner AR, Marshall-Batty KR, Arora K, Zhao M, Martin R, Ding L, Hammer CH, Shaw PA, Kuhns DB, Malech HL, Gallin JI, Zarember KA, Holland SM.

J Infect Dis. 2012 Sep 15;206(6):943-51. doi: 10.1093/infdis/jis431. Epub 2012 Jul 10.

4.

Identification of a novel Staphylococcus aureus two-component leukotoxin using cell surface proteomics.

Ventura CL, Malachowa N, Hammer CH, Nardone GA, Robinson MA, Kobayashi SD, DeLeo FR.

PLoS One. 2010 Jul 16;5(7):e11634. doi: 10.1371/journal.pone.0011634.

5.

Identification of conserved antigens for early serodiagnosis of relapsing fever Borrelia.

Lopez JE, Porcella SF, Schrumpf ME, Raffel SJ, Hammer CH, Zhao M, Robinson MA, Schwan TG.

Microbiology. 2009 Aug;155(Pt 8):2641-51. doi: 10.1099/mic.0.029918-0. Epub 2009 May 14.

6.

Towards a rational approach for heavy-atom derivative screening in protein crystallography.

Agniswamy J, Joyce MG, Hammer CH, Sun PD.

Acta Crystallogr D Biol Crystallogr. 2008 Apr;64(Pt 4):354-67. doi: 10.1107/S0907444907068849. Epub 2008 Mar 19.

7.

Comparative sialomics between hard and soft ticks: implications for the evolution of blood-feeding behavior.

Mans BJ, Andersen JF, Francischetti IM, Valenzuela JG, Schwan TG, Pham VM, Garfield MK, Hammer CH, Ribeiro JM.

Insect Biochem Mol Biol. 2008 Jan;38(1):42-58. Epub 2007 Sep 25.

8.

Global analysis of community-associated methicillin-resistant Staphylococcus aureus exoproteins reveals molecules produced in vitro and during infection.

Burlak C, Hammer CH, Robinson MA, Whitney AR, McGavin MJ, Kreiswirth BN, Deleo FR.

Cell Microbiol. 2007 May;9(5):1172-90. Epub 2007 Jan 9.

9.

Characterization of a lysyl aminopeptidase activity associated with phosphoglucose isomerase of Vibrio vulnificus.

Richards GP, Hammer CH, Garfield MK, Parveen S.

Biochim Biophys Acta. 2004 Aug 2;1700(2):219-29.

PMID:
15262231
10.

Mass-spectrometry assisted heavy-atom derivative screening of human Fc gamma RIII crystals.

Sun PD, Hammer CH.

Acta Crystallogr D Biol Crystallogr. 2000 Feb;56(Pt 2):161-8.

PMID:
10666595
11.

C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway.

Nilsson G, Johnell M, Hammer CH, Tiffany HL, Nilsson K, Metcalfe DD, Siegbahn A, Murphy PM.

J Immunol. 1996 Aug 15;157(4):1693-8.

PMID:
8759757
12.

Production and characterization of the monoclonal antibody against SGP120, a novel serum protein.

Basta M, Miletic VD, Hammer CH, Frank MM.

Hybridoma. 1996 Feb;15(1):69-75.

PMID:
9064288
13.

Further identification of human plasma glycoproteins interacting with the galactose-specific lectin Jacalin.

Pilatte Y, Rostoker G, Violleau K, Basta M, Hammer CH.

J Chromatogr B Biomed Appl. 1995 Jun 9;668(1):1-11.

PMID:
7550965
14.
15.

Potassium cyanide protects Escherichia coli from complement killing by the inhibition of C3 convertase activity.

Bloch EF, Rahbar M, Wright AK, Patterson AM, Souza RF, Hammer CH, Gaither TA, Joiner KA.

Immunol Invest. 1993 Mar;22(2):127-49.

PMID:
8505069
16.

Regulation of complement activity by vaccinia virus complement-control protein.

McKenzie R, Kotwal GJ, Moss B, Hammer CH, Frank MM.

J Infect Dis. 1992 Dec;166(6):1245-50.

PMID:
1431243
17.

A rapid FPLC method for purification of the third component of human and guinea pig complement.

Basta M, Hammer CH.

J Immunol Methods. 1991 Aug 28;142(1):39-44.

PMID:
1919020
18.

Serum resistance of metacyclic stage Leishmania major promastigotes is due to release of C5b-9.

Puentes SM, Da Silva RP, Sacks DL, Hammer CH, Joiner KA.

J Immunol. 1990 Dec 15;145(12):4311-6.

PMID:
2147941
19.

Generation of C5-dependent bioactivity by tissue-bound anti-BMZ autoantibodies.

Gammon WR, Yancey KB, Mangum KL, Hendrix JD, Hammer CH.

J Invest Dermatol. 1989 Aug;93(2):195-200.

20.

Multimeric C9 within C5b-9 deposits in unique locations in the cell wall of Salmonella typhimurium.

Joiner KA, Tartanian AB, Hammer CH, Schweinle JE.

J Immunol. 1989 Jun 15;142(12):4450-7.

PMID:
2656866
21.

A new simplified procedure for C1 inhibitor purification. A novel use for jacalin-agarose.

Pilatte Y, Hammer CH, Frank MM, Fries LF.

J Immunol Methods. 1989 Jun 2;120(1):37-43.

PMID:
2732474
22.
23.
24.

Interactions of a nonneutralizing IgM antibody and complement in parainfluenza virus neutralization.

Vasantha S, Coelingh KL, Murphy BR, Dourmashkin RR, Hammer CH, Frank MM, Fries LF.

Virology. 1988 Dec;167(2):433-41.

PMID:
2849234
25.

Identification of membrane components of Trypanosoma cruzi modulators of complement system.

Kipnis TL, Joiner KA, da Silva WD, Rimoldi MT, Hammer CH, Sher A.

Mem Inst Oswaldo Cruz. 1988 Nov;83 Suppl 1:571-5. No abstract available.

26.

Biochemical characterization of a factor produced by trypomastigotes of Trypanosoma cruzi that accelerates the decay of complement C3 convertases.

Joiner KA, daSilva WD, Rimoldi MT, Hammer CH, Sher A, Kipnis TL.

J Biol Chem. 1988 Aug 15;263(23):11327-35.

27.

Acquired angioedema: observations on the mechanism of action of autoantibodies directed against C1 esterase inhibitor.

Malbran A, Hammer CH, Frank MM, Fries LF.

J Allergy Clin Immunol. 1988 Jun;81(6):1199-204.

PMID:
2454251
28.

Developmentally regulated expression by Trypanosoma cruzi of molecules that accelerate the decay of complement C3 convertases.

Rimoldi MT, Sher A, Heiny S, Lituchy A, Hammer CH, Joiner K.

Proc Natl Acad Sci U S A. 1988 Jan;85(1):193-7.

29.

A complement-resistant HeLa cell line (T638) is blocked at the step of C3 deposition.

Santi P, Joiner KA, Hammer CH, Frank MM, Tosi R.

J Immunol. 1987 May 15;138(10):3385-91.

PMID:
2952716
30.

Purification of C1 inhibitor. A new approach for the isolation of this biologically important plasma protease inhibitor.

Prograis LJ Jr, Hammer CH, Katusha K, Frank MM.

J Immunol Methods. 1987 May 4;99(1):113-22.

PMID:
3553333
31.

Nucleated cell killing by complement: effects of C5b-9 channel size and extracellular Ca2+ on the lytic process.

Kim SH, Carney DF, Hammer CH, Shin ML.

J Immunol. 1987 Mar 1;138(5):1530-6.

PMID:
2433349
32.

Terminal complement components play a role in the expression of C5a.

Gresham HD, Renfer L, Hammer CH, Frank MM.

J Immunol. 1987 Feb 1;138(3):838-41.

PMID:
3805718
33.

Multimeric C9 within C5b-9 is required for inner membrane damage to Escherichia coli J5 during complement killing.

Bloch EF, Schmetz MA, Foulds J, Hammer CH, Frank MM, Joiner KA.

J Immunol. 1987 Feb 1;138(3):842-8.

PMID:
3100618
34.

Inhibition of complement by culture supernatants of Aspergillus fumigatus.

Washburn RG, Hammer CH, Bennett JE.

J Infect Dis. 1986 Dec;154(6):944-51.

PMID:
3537152
35.

Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade.

Fries LF, Friedman HM, Cohen GH, Eisenberg RJ, Hammer CH, Frank MM.

J Immunol. 1986 Sep 1;137(5):1636-41.

PMID:
3018078
37.

Release of arachidonic acid and formation of oxygenated derivatives after complement attack on macrophages: role of channel formation.

Imagawa DK, Osifchin NE, Ramm LE, Koga PG, Hammer CH, Shin HS, Mayer MM.

J Immunol. 1986 Jun 15;136(12):4637-43.

PMID:
3086438
38.

Immunoregulatory disorders associated with hereditary angioedema. II. Serologic and cellular abnormalities.

Brickman CM, Tsokos GC, Chused TM, Balow JE, Lawley TJ, Santaella M, Hammer CH, Linton GF, Frank MM.

J Allergy Clin Immunol. 1986 May;77(5):758-67.

PMID:
3486201
39.

Immunoregulatory disorders associated with hereditary angioedema. I. Clinical manifestations of autoimmune disease.

Brickman CM, Tsokos GC, Balow JE, Lawley TJ, Santaella M, Hammer CH, Frank MM.

J Allergy Clin Immunol. 1986 May;77(5):749-57.

PMID:
3084606
40.

A simplified method for purification of human C5a from citrated plasma.

Renfer L, Frank MM, Hammer CH, Harvath L, Lawley TJ, Yancey KB.

J Immunol Methods. 1986 Apr 17;88(2):193-205.

PMID:
3514765
41.

Quantitation of activation of the human terminal complement pathway by ELISA.

Sanders ME, Schmetz MA, Hammer CH, Frank MM, Joiner KA.

J Immunol Methods. 1985 Dec 27;85(2):245-56.

PMID:
2416846
42.
43.

Multimeric complement component C9 is necessary for killing of Escherichia coli J5 by terminal attack complex C5b-9.

Joiner KA, Schmetz MA, Sanders ME, Murray TG, Hammer CH, Dourmashkin R, Frank MM.

Proc Natl Acad Sci U S A. 1985 Jul;82(14):4808-12.

44.

Purification of the third component of canine complement.

Johnson JP, Hammer CH, Winkelstein JA.

Vet Immunol Immunopathol. 1985 Apr;8(4):377-89.

PMID:
4002610
45.

Studies of human C5a as a mediator of inflammation in normal human skin.

Yancey KB, Hammer CH, Harvath L, Renfer L, Frank MM, Lawley TJ.

J Clin Invest. 1985 Feb;75(2):486-95.

46.

C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I.

Fries LF, Gaither TA, Hammer CH, Frank MM.

J Exp Med. 1984 Dec 1;160(6):1640-55.

47.

A quantitative analysis of C3 binding to O-antigen capsule, lipopolysaccharide, and outer membrane protein of E. coli 0111B4.

Joiner KA, Goldman R, Schmetz M, Berger M, Hammer CH, Frank MM, Leive L.

J Immunol. 1984 Jan;132(1):369-75.

PMID:
6197449

Supplemental Content

Loading ...
Support Center